COVID-19 vaccination: The road ahead

  title={COVID-19 vaccination: The road ahead},
  author={Daniel M. Altmann and Rosemary J. Boyton},
  pages={1127 - 1132}
A diverse array of successful, first-generation SARS-CoV-2 vaccines have played a huge role in efforts to bring the COVID-19 pandemic under control, even though inequitable distribution still leaves many vulnerable. Additional challenges loom for the next phase. These include optimizing the immunological rationale for boosting—how often and with what—and the best approaches for building a future-proofed, durable immune repertoire to protect against oncoming viral variants, including in children… 
Grand Challenges in Vaccine Delivery: Lessons Learned From the COVID-19 Vaccine Rollout
  • C. Foged
  • Medicine
    Frontiers in Drug Delivery
  • 2022
Although the COVID-19 pandemic is not over yet, the authors are moving beyond the emergency response and are adapting to live alongside with the virus, while strategies are being developed for handling the lasting threat of SARS-CoV-2.
Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
Understanding COVID-19 Vaccines Today: Are T-cells Key Players?
The role of T-cells is essential to understanding the broader adaptive immune response to COVID-19, which has the potential to shape public policies on vaccine protocols and inform future vaccine design.
From Prevention to Therapy: A Roadmap of Nanotechnologies to Stay Ahead of Future Pandemics
This perspective is intended to outline how nanotechnology can be employed to improve upon respiratory disease detection and containment measures, and therapeutics, with a particular emphasis on applications that can address key areas, including home diagnostics, contact tracing, and the evaluation of durability of vaccine protection over time and against future variants.
The Impact of COVID-19 Vaccine Coverage on Deaths Outcome in Africa, Subregional Differences and the need for a Renewed Multi-level Effort
This study indicates that a relation exists between total deaths and the variables confirmed cases, doses administered, and fully vaccinated and that African countries grouped in geographical subregions perform differently in terms of vaccine rollout, and that offers insights for better and oriented interventions.
Correlates of protection for booster doses of the BNT162b2 vaccine
It is demonstrated that following immunization with three or four vaccine doses, combinations of IgA and IgG levels are associated with protection from symptomatic infection, and a subpopulation of healthy adult individuals with low-baseline levels of antibodies after 3 doses which are at an increased risk for SARS-CoV-2 infection despite receiving a fourth dose.
The immunology and immunopathology of COVID-19
It is hoped that the knowledge gained from this COVID-19 research will be applied in studies of inflammatory processes involved in critical and chronic illnesses, which remain a major unmet need.
Building pyramids against the evolutionary emergence of pathogens
This work shows that pyramiding multiple defenses into the same individual host and avoiding mixing with single-defense strategies is a robust way to protect individuals and populations against pathogen evolutionary emergence.
The connection between COVID-19 vaccine abundance, vaccination coverage, and public trust in government across the globe
This study investigates that how the number of COVID-19 vaccines secured correlates with the vaccination coverage (full and booster) depending on whether there is trust in national government or not


Viral targets for vaccines against COVID-19
As the world races to develop vaccines against SARS-CoV-2, Dai and Gao highlight which viral targets are best to include in a vaccine and how this impacts the induced immune response and the safety and efficacy of a vaccine.
Looking beyond COVID-19 vaccine phase 3 trials.
After the recent announcement of COVID-19 vaccine efficacy in clinical trials by several manufacturers for protection against severe disease, a comprehensive post-efficacy strategy for the next steps
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape
A snapshot of ongoing vaccine efficacy studies, as well as real-world data on vaccine effectiveness and the impact of virus variants of concern are provided.
SARS-CoV-2 variants, spike mutations and immune escape
The literature on mutations of the SARS-CoV-2 spike protein, the primary antigen, is summarized, focusing on their impacts on antigenicity and contextualizing them in the protein structure, and discussed in the context of observed mutation frequencies in global sequence datasets.
Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
Analysis of T and B cell responses after first-dose vaccination with the Pfizer/BioNTech messenger RNA vaccine BNT162b2 in health care workers followed longitudinally, with or without prior SARS-CoV-2 infection found enhanced T cell immunity, antibody-secreting memory B cell response to the spike protein, and neutralizing antibodies effective against variants.
A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
The quality of immune responses triggered and the rapid kinetics by which protective immunity can be mounted already after a single dose warrant further development of this potent SARS-CoV-2 vaccine candidate.
Immunity to SARS-CoV-2 variants of concern
There is concern about reduced vaccine-induced immune protection to emerging variants that have mutations in the spike protein, but there is likely sufficient efficacy remaining to confer protection from symptomatic disease.
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
These findings demonstrate multicomponent immune memory after SARS-CoV-2 mRNA vaccination, with memory B and T cell responses remaining durable even as antibodies decline, although antibodies did decline over time.
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Data suggest that protection may require low levels of NAbs and might involve other immune effector mechanisms including non-NAbs, T cells and innate immune mechanisms, as well as potent T cell responses.
Immune imprinting and SARS-CoV-2 vaccine design